Beta Drugs (NSE:BETA) Inventory Turnover: 0.48 (As of Mar. 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
91 GF Score
Price ₹2,366.80
GF Value ₹1,975.60
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Inventory Turnover?

Beta Drugs NSE:BETA +8.06% 91 Inventory Turnover is 0.48 as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 91/100 and a GF Value™ of ₹1,975.60 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Beta Drugs's Cost of Goods Sold for the three months ended in Mar. 2026 was ₹361 Mil. Beta Drugs's Average Total Inventories for the quarter that ended in Mar. 2026 was ₹745 Mil. Beta Drugs's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.48.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Beta Drugs's Days Inventory for the three months ended in Mar. 2026 was 188.24.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Beta Drugs's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.79.

Beta Drugs  (NSE:BETA) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Beta Drugs's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=744.639/360.962*365 / 4
=188.24

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Beta Drugs's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=744.639 / 939.649
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Beta Drugs Inventory Turnover Related Terms

Beta Drugs Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Inventory Turnover Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 4.88 4.51 3.13 2.55

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.74 0.00 0.49 0.48
NSE:BETA
91GF Score
Beta Drugs Ltd NSE:BETA
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Inventory Turnover Calculation

Beta Drugs's Inventory Turnover for the fiscal year that ended in Mar. 2026 is calculated as

Inventory Turnover (A: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Mar. 2026 ) / ((Total Inventories (A: Mar. 2025 ) + Total Inventories (A: Mar. 2026 )) / count )
=1711.799 / ((597.726 + 744.639) / 2 )
=1711.799 / 671.1825
=2.55

Beta Drugs's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=360.962 / ((0 + 744.639) / 1 )
=360.962 / 744.639
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.48 mean?
Beta Drugs (NSE:BETA) has a Inventory Turnover of 0.48 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Inventory Turnover too high?
Beta Drugs' current Inventory Turnover is 0.48. Overall, Beta Drugs has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Inventory Turnover compare to ZTS and UTHR?
Beta Drugs' Inventory Turnover of 0.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Drug Manufacturers company?
A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Beta Drugs and its competitors. Beta Drugs's current Inventory Turnover is 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,975.60, compared to a current price of ₹2,366.80 — trading 19.8% above its estimated fair value. The current Inventory Turnover is 0.48. Beta Drugs' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Inventory Turnover is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,366.80 is trading 19.8% above its estimated GF Value™ of ₹1,975.60. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

  • Inventory Turnover: 0.48
  • GF Value™: ₹1,975.60 vs. price of ₹2,366.80 (19.8% above fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score

Get the complete analysis for NSE:BETA

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,366.80
Price
₹1,975.60
GF Value